Elder Pharmaceuticals Ltd

BSE: 532322
₹38.00
▲ 1.80 (4.97%)
Sept. 12, 2016 · BSE · bse_bhavcopy
Quality
—/100
Data unavailable
Valuation
—/100
Data unavailable
Momentum
54/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Elder Pharmaceuticals Ltd was a pharmaceutical company headquartered in Mumbai, Maharashtra. Its main activities included the manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices. It had 6 manufacturing plants in India & 1 in Nepal. It manufactured various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.

Source: Wikipedia

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
6.9
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
Data unavailable.
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
Data unavailable (needs a filed half-yearly balance sheet).
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
Data unavailable.
Net Margin
Data unavailable.
Operating Margin (EBIT)
Data unavailable.
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Value and momentum

2 of 4 met
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
5.0%
Low 37.1000 · High 38.0000
1W return
10.1%
Low 33.0000 · High 38.0000
1M return
27.1%
Low 31.0000 · High 38.0000
52W return
-64.5%
Low 20.3500 · High 118.8000
Lifetime High ₹457.8500 (Sept. 18, 2007)
Lifetime Low ₹21.4000 (June 20, 2016)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish3
5D
34.8
10D
32.2
20D
31.5
50D
39.9
100D
54.6
200D
80.7

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

37.70
Pivot
First resistance38.30
Second resistance38.60
Third resistance39.20
First support37.40
Second support36.80
Third support36.50
Day RSI63.0
Day MFI93.6
Day MACD-0.91
Day MACD signal-3.27

Beta

1M—
3M—
1Y0.45
3Y1.00

Price change analysis

↑ 27.1%
Over 1 Month
LowHigh
31.0038.00
↑ 68.9%
Over 3 Months
LowHigh
20.3538.00
↓ -8.8%
Over 6 Months
LowHigh
20.3541.35
↓ -64.5%
Over 1 Year
LowHigh
20.35118.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Data unavailable.

Shareholding pattern / Ownership

Data unavailable.

Full shareholding pattern →

DateClientDealActionQuantityPriceExchange
5 Jan 2015 MILLENNIUM STOCK BROKING PVT LTD Bulk Sell 198,227 161.5100 BSE
5 Jan 2015 MILLENNIUM STOCK BROKING PVT LTD Bulk Buy 198,280 161.3800 BSE
25 Mar 2014 MONET SECURITIES P LTD Bulk Buy 123,310 194.1000 BSE
25 Mar 2014 SUPREME WOOD PRODUCTS PVT. LTD Bulk Sell 123,310 194.1000 BSE
1 Jan 2014 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 107,283 253.7500 BSE
1 Jan 2014 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 107,501 254.7800 BSE
13 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 208,940 315.7100 BSE
13 Dec 2013 CROSSEAS CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 208,940 316.5100 BSE
5 Nov 2012 ELDER PHARMA EMPLOYEES WELFARE TRUST Bulk Sell 150,000 302.3700 BSE
28 Jul 2011 ALMONDZ CAPITAL & MANAGEMENT Bulk Sell 103,500 411.0500 BSE

All bulk and block deals →

Ex-dateSubjectPer share (₹)Record date
17 Sep 2012 Annual General Meeting And Dividend Rs.3/- Per Share 3.0000 —
15 Sep 2011 Dividend-Rs.3/- Per Share 3.0000 —
16 Sep 2010 Dividend-Rs.3/- Per Share 3.0000 —
17 Sep 2009 Dividend-Rs.2.50 Pr Share 2.5000 —
18 Sep 2008 Agm/Dividend - 25% — —
18 Sep 2007 Agm/Dividend-25% — —
21 Sep 2006 Agm/Dividend-25% — —
15 Sep 2005 Agm/Dividend-25% — —

Corporate Actions

Full history (10 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
22 Dec 2014AGMAnnual General Meeting (Agm & Book Closure Dates Revised)
19 Dec 2013OTHERAnnual General Meeting

All corporate actions →

Corporate Announcements

All 131 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
18 May 2018 Delisting Members of the Exchange are hereby notified that in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957, it has been decided to delist (withdraw the admission to dealings in) equity shares of the Elder Pharmaceuticals Limited w.e.f. May 30, 2018.
28 Feb 2018 Public Notice - Compulsory Delisting Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).
5 Jun 2017 News Clarification The Exchange has sought clarification from the Company with respect to news item captioned "Elder Pharma files for Insolvency". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
21 Jul 2016 News Clarification The Exchange has sought clarification from Elder Pharmaceuticals Limited with respect to recent news item captioned ''Elder Pharma, embroiled in bribery case, is among the biggest defaulters and the Ministry is doing nothing''. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under regulation 30 of Listing regulations. The response from the Company is awaited.
3 Feb 2016 Outcome of Board Meeting Elder Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on February 03, 2016.
25 Jan 2016 Appointment of Director Elder Pharmaceuticals Limited has informed the Exchange that the Promoter have appointed Non-Executive Independent Directors i.e. Mr. Ravani Mohammed Abdul Khader and Mr. Kader Mohammed Davawala as Additional Directors w.e.f. January 25, 2016. Further Dr. (Mrs.) Babita Bhatia was appointed as Additional Director on July 15, 2015 who shall hold office up to the date of the next Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier. The last date of the Annual General Meeting was December 31, 2015 and the same is delayed. Therefore , she is removed from the directorship w.e.f.January 01 , 2016 as per. the provisions of the Companies Act, 2013.
18 Dec 2015 Shifting of security to Z category Members of the Exchange are hereby informed that trading in Equity shares of Elder Pharmaceuticals Limited shall be transferred to BZ series with effect from December 28, 2015 due to non-compliances of the Clause 41 of the Listing Agreement for two consecutive quarters i.e. June 2015 and September 2015.
29 Oct 2015 Resignation of Director Elder Pharmaceuticals Limited has informed the Exchange that Dr. Sailendra Narain as Non -Executive Independent Director has tendered his resignation as Director of the company with effect from October 20, 2015.Further Company would like to thanks to Dr. Sailendra Narain for the assistance and guidance provided by him during his tenure as Director of the company.Company is in process to find right candidate for appointment of Additional Director on the Board to comply with the requirement as per Companies Act, 2013 and corporate Governance norms under clause 49 of listing agreement.
29 Oct 2015 Resignation of Director Elder Pharmaceuticals Limited has informed the Exchange that Dr. Joginder Singh Juneja as Non -Executive Independent Director has tendered his resignation as Director of the company with effect from October 21, 2015.Further Company would like to thanks to Dr. Joginder Singh Juneja for the assistance and guidance provided by him during his tenure as Director of the company.Company is in process to find right candidate for appointment of Additional Director on the Board to comply with the requirement as per Companies Act, 2013 and corporate Governance norms under clause 49 of listing agreement.
12 Oct 2015 News Clarification Elder Pharmaceuticals Limited has informed the Exchange vide letter dated October 12, 2015 regarding Clarification on various reports in News Papers.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • Down 64.5% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Elder Pharmaceuticals Ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.